Ovarian Function Suppression Plus Aromatase Inhibitors or Tamoxifen in Premenopausal HR-positive Breast Cancer

Abstract

OFS also makes AIs applicable to premenopausal women. Generally speaking, AIs are not used in premenopausal patients, because ovarian function will increase the production of aromatase, causing AIs to lose efficacy. After using Als in postmenopausal patients, the estrogen concentration of the patients may not be detectable [18].